Transforming Lives: The Impact of Cell and Gene Therapy on Modern Medicine

As cell and gene therapies advance from clinical development to commercial manufacturing, ensuring consistent product quality has become a top priority. Unlike conventional pharmaceuticals, these products are composed of living cells or genetic material that are highly sensitive to manufacturing conditions. A comprehensive Release Testing strategy verifies that every batch meets predefined quality specifications before it reaches patients. When combined with robust in-process testing, release testing forms the foundation of quality assurance for Advanced Therapy Products (ATPs). In 2026, regulatory agencies continue to strengthen expectations for product characterization, analytical validation, and quality control. Manufacturers that implement well-designed release testing programs are better positioned to reduce batch failures, support regulatory submissions, and accelerate commercialization. What Is Release Testing? Release Testing is the final quality assessment performed after man...

Cell therapies are transforming the treatment of cancer, autoimmune disorders, and rare diseases, but their success depends on maintaining strict quality standards throughout development and manufacturing. Since these products consist of living cells, manufacturers must accurately identify, characterize, and monitor cell populations to ensure product safety, consistency, and efficacy. This is where flow cytometry immunophenotyping plays a vital role. As the cell and gene therapy industry expands in 2026, flow cytometry has become one of the most widely used analytical techniques for confirming cell identity, assessing purity, and supporting regulatory compliance. When integrated into Current Good Manufacturing Practice (cGMP) workflows, it helps manufacturers generate reliable analytical data that supports successful product development and commercialization. What Is Flow Cytometry Immunophenotyping? Flow cytometry immunophenotyping is an analytical technique that identifies and quant...

Natural killer (NK) cell therapies are gaining significant attention in the cell and gene therapy industry. Their ability to recognize and eliminate tumor cells without prior sensitization has positioned them as a promising alternative to other cell-based immunotherapies. As clinical pipelines expand, NK cell manufacturing is becoming a major focus for biotechnology companies seeking scalable and cost-effective therapeutic platforms. However, moving NK cell therapies from research to commercialization presents several manufacturing and operational challenges. In 2026, the industry is increasingly focused on improving manufacturing efficiency, enabling allogeneic production, and developing scalable platforms that support commercial growth. Why NK Cell Therapies Are Gaining Momentum NK cells offer several advantages compared with other cell therapies: Lower risk of graft-versus-host disease (GvHD) Potential for off-the-shelf manufacturing Broad anti-tumor activity Compatibility with com...

Cell therapy products are, quite literally, made of cells — which means proving what those cells actually are is one of the most fundamental steps in demonstrating product identity, purity, and safety. That's where flow cytometry immunophenotyping comes in. It's one of the most widely used analytical techniques in cell therapy development, and understanding how it works — and where it fits into your testing strategy — matters for anyone bringing a cell therapy product toward the clinic. What Is Flow Cytometry Immunophenotyping? Flow cytometry immunophenotyping is a technique used to identify and characterize cell populations based on the surface and intracellular markers they express. Cells are labeled with fluorescently tagged antibodies that bind to specific proteins — such as CD3, CD4, CD8, CD19, or CD56, depending on the therapy — and then passed single-file through a laser-based detection system. As each cell passes through, the instrument measures the fluorescence and ...